US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.44 against a street estimate of 0.27 — a beat of 63.0%.
Analysts rate Pacira BioSciences, Inc. a buy (5 buy, 3 hold, 1 sell out of 9) with an average price target of $30.11.
| Fund | Stake |
|---|---|
| BlackRock Inc | 16.82% |
| Doma Perpetual Capital Management LLC | 6.97% |
| Vanguard Portfolio Management, LLC | 6.04% |
| Dimensional Fund Advisors, Inc. | 5.28% |
| State Street Corp | 5.17% |
| D. E. Shaw & Co LP | 4.89% |
| Renaissance Technologies Corp | 4.35% |
| Vanguard Capital Management, LLC | 4.24% |
| Document | Date |
|---|---|
| Material agreement · Q4 2026 HEADLINE NUMBERS • Pacira BioSciences entered into a merger agreement with Viatris Inc. on October 8, 2026. • Viatris will offer $36.50 in cash for | 2026-10-08 |
| Quarterly report · Q2 2026 PACIRA BIOSCIENCES, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net product sales Q2 2026: $190.5 million (vs. $180.3 million Q2 2025) — 5.6% inc | 2026-08-04 |
| Results announced · Q3 2026 PACIRA BIOSCIENCES Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total Q2 2026 revenue: $192.4 million (6% YoY growth vs. $181.1 million in Q2 2025) | 2026-08-04 |
| Material agreement · Q2 2026 PACIRA BIOSCIENCES, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Total deal value: Up to $140 million ($70 million upfront + up to $70 million in cont | 2026-06-30 |
| Board / officer change · Q2 2026 PACIRA BIOSCIENCES, INC. — FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company held 2026 Annual Meeting of Stockholders on June 9, 2026 in Pars | 2026-06-11 |
| Quarterly report · Q1 2026 PACIRA BIOSCIENCES, INC. – Q1 2026 SUMMARY HEADLINE NUMBERS • Net product sales Q1 2026: $177.4 million (vs. $167.6 million Q1 2025) – 5.8% increase | 2026-04-30 |
| Results announced · Q2 2026 PACIRA BIOSCIENCES Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Total revenue: $177.4 million (5% increase vs Q1 2025's $168.9 million) • GA | 2026-04-30 |
| Annual report FY2025 PACIRA BIOSCIENCES, INC. — FORM 10-K SUMMARY HEADLINE NUMBERS • Fiscal year ended December 31, 2025 • Company trades as PCRX on Nasdaq Global Select | 2026-02-26 |
Readable in the app.
| Announcement | Date |
|---|---|
| Viatris agreed to acquire Pacira BioSciences through a cash tender offer and merger Pacira BioSciences agreed to be acquired by Viatris in an all-cash tender offer. Viatris will offer $36.50 per Pacira share, with the offer expected to begin within 15 business days of Octob | 2026-10-08 |
| Company agrees to divest cryoanalgesia device business to Zimmer for up to $140 million Pacira BioSciences agreed to sell its handheld cryoanalgesia device business, including iovera, to Zimmer Biomet subsidiary Zimmer, Inc. The deal is expected to close in the third quarter of | 2026-06-30 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pacira BioSciences, Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.